HomeInvesting NewsSorrento Stock Price Down 5.3%

Sorrento Stock Price Down 5.3%

Published on

On Monday, the price of Sorrento stock (NASDAQ:SRNE) fell 5.3%. The stock dropped as low as $1.76 before closing at $1.77. During midday trading, 98,281 shares changed hands, representing a 99% decrease from the average session volume of 9,258,171 shares. SNRE stock(NASDAQ:SRNE) had previously closed at $1.87.

Sorrento Stock Performance

Currently, the company has a 50-day moving average of $2.33 and a 200-day moving average of $2.07. The quick ratio is 1.21, the current ratio is 1.35, and the debt-to-equity ratio is 0.61.

Sorrento Therapeutics Insider Trading

On Thursday, August 25th, insider Henry Ji acquired 22,222 shares of SNRE stock (NASDAQ:SRNE). The shares were acquired for $45,777.32 at an average cost of $2.06 per share. Following the transaction, the insider now owns 2,088,029 shares of SNRE stock (NASDAQ:SRNE) worth $4,301,339.74. The transaction was reported in a filing with the Securities and Exchange Commission. Corporate insiders now hold 3.30% of the stock.

Inflows and Outflows of Institutional Funds

SNRE stock (NASDAQ:SRNE) has lately been purchased and sold by several hedge funds and other institutional investors. In the first quarter, Goelzer Investment Management Inc. purchased a new investment in Sorrento Therapeutic for about $28,000. Stratos Wealth Partners LTD. bought a new stake in Sorrento Therapeutics for about $30,000 in the first quarter. Telemus Capital LLC purchased a new investment in Sorrento Therapeutics in the first quarter for about $31,000. In the second quarter, B. Riley Wealth Management Inc. purchased a new investment in Sorrento Therapeutics for about $11,363,000. Finally, in the second quarter, Corient Capital Partners LLC purchased a new position in Sorrento Therapeutics for about $30,000. Hedge funds and other institutional investors hold 33.61% of SNRE stock in total.

Sorrento Therapeutics Information:

Sorrento Therapeutics, Inc. is a clinical and commercial biopharmaceutical business that discovers treatments for cancer, autoimmune, inflammatory, viral, and neurological illnesses. It works in two divisions: Sorrento Therapeutics and Scilex. The company offers cancer therapies by leveraging its proprietary G-MAB antibody library and targeted delivery modalities.

Featured Image – Megapixl © Thecriss 

Please See Disclaimer

Latest News

Analysts Think FedEx Corp Must Slash Costs as Investor Patience Wanes

Wall Street analysts said on Friday that FedEx Corp (NYSE:FDX) Corp's new chief executive...

Monterey Private Sells Cisco Stock.

According to its most recent 13F filing with the Securities and Exchange Commission, Monterey...

General Motors Hummer EV Demand Exceeds Production Capacity

Forget about inflation, interest rates, and the possibility of a recession; people are interested...

Berkshire Stock Gets a Buy Rating From Edward Jones.

Berkshire Stock (NYSE:BRK.A) Stock analysts at Edward Jones raised Berkshire stock (NYSE:BRK.A) from a "hold"...

More like this

Royal Caribbean Stock Slides, Debt Financing, and Credit Suisse Maintains Its Positive Outlook

Royal Caribbean stock was trading at $44.41 s of 11:30 AM EDT on Friday. To...

Microsoft Corporation Plays The Real Game With Activision

Here's a proposal if Microsoft Corporation (NASDAQ: MSFT) 0.85% wants to earn real money...

Costco Wholesale Corporation Is Affected By Inflation and Increase in Membership Fee

Costco Wholesale Corporation (NASDAQ:COST) considers what some businesses are saying about inflation because the...

Roku Stock is Not Down and Out Yet.

To say Roku stock (NASDAQ:ROKU) has had a horrible year would be an understatement....

Apple Inc Is The Last Standing Tech Company

As a result of the renewed selling pressure on US stock indices, we are...

Costco Wholesale Corporation Earnings Have Been Exceeding Analyst Predictions, And Membership Fees Have Reached $1.3 Billion

Costco Wholesale Corporation's revenues for the three months ending in August surpassed $72 billion,...